10-OR: In Women with Prior Gestational Diabetes Mellitus, the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Glucose Tolerance Irrespective of Body Weight Loss after Five Years of Treatment, but Effects Are Lost after Wash-Out

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 10-OR
Author(s):  
EMILIE S. ANDERSEN ◽  
SIGNE FOGHSGAARD ◽  
LOUISE VEDTOFTE ◽  
MARIE H. PEDERSEN ◽  
JULIE FORMAN ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Weight Loss ◽  
Body Weight ◽  
Gestational Diabetes ◽  
Glucose Tolerance ◽  
Gestational Diabetes Mellitus ◽  
Receptor Agonist ◽  
Body Weight Loss ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

2020 ◽  
Vol 9 (10) ◽  
pp. 3213
Author(s):  
Louise Vedtofte ◽  
Emilie Bahne ◽  
Signe Foghsgaard ◽  
Jonatan I. Bagger ◽  
Camilla Andreasen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Liver Disease ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Fatty Liver Disease ◽  
Transient Elastography ◽  
Nonalcoholic Fatty Liver ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Prior gestational diabetes mellitus (pGDM) is associated with increased risk of nonalcoholic fatty liver disease (NAFLD). Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has shown beneficial effects in NAFLD patients. We evaluated the effect of the GLP-1 analogue liraglutide on NAFLD features in women with pGDM. Eighty-two overweight/obese, nondiabetic women with pGDM were included. We performed abdominal ultrasound, transient elastography with controlled attenuation parameter (CAP), and blood sampling at baseline and after 1 year. Thirty-seven women were randomized to liraglutide (1.8 mg once-daily) and 45 to placebo. Based on the ultrasound scan, 18 women (22%) had ultrasound-verified NAFLD at baseline and of these, 10 (56%) received liraglutide treatment. After 1 year, eight participants no longer had steatosis, four in each treatment group. The number of participants who developed NAFLD was similar in the two treatment groups; five in the liraglutide group and six in the placebo group (p = 0.74). Compared to placebo, liraglutide reduced the CAP-assessed intrahepatic fat content (−28 (−44;−11) vs. 2 (−13;18) dB/m, p < 0.01) and body weight (−4.7 (−6.4;−2.9) vs. −1.4 (−3;0.3) kg, p < 0.01). One-year’s liraglutide treatment had no effect on the presence of ultrasound-diagnosed NAFLD in overweight/obese nondiabetic women with pGDM, but reduced body weight and steatosis assessed by transient elastography with CAP.

Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus

2007 ◽  
Vol 23 (1) ◽  
pp. 58-62 ◽  
Author(s):  
Katarzyna Cypryk ◽  
Tina Vilsbøll ◽  
Iwona Nadel ◽  
Joanna Smyczyńska ◽  
Jens Juul Holst ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Incretin Hormones ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON PATIENTS WITH DIABETES ON INSULIN THERAPY

2019 ◽  
Vol 25 (9) ◽  
pp. 935-942 ◽  
Author(s):  
Janelle B. Gyorffy ◽  
Andrea N. Keithler ◽  
Jana L. Wardian ◽  
Lee A. Zarzabal ◽  
Alexander Rittel ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Weight Loss ◽  
Insulin Therapy ◽  
Receptor Agonist ◽  
Hemoglobin A1c ◽  
High Dose ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Basal Bolus ◽  
The Impact

Objective: The clinical benefit of adding a glucagon-like peptide-1 receptor agonist (GLP-1RA) to basal-bolus or very high dose insulin regimens is unclear. This study investigated the impact of adding a GLP-1RA to a spectrum of insulin regimens (basal, basal-bolus, and U-500) to determine the impact on hemoglobin A1c (HbA1c), weight loss, and total daily insulin dose (TDD) over the course of 12 months. Methods: A retrospective chart review was conducted on 113 participants with type 2 diabetes mellitus using insulin therapy. Each participant's HbA1c, body weight, and TDD were recorded prior to initiation of GLP-1RA therapy and at the 3, 6, and 12-month time points while on combination therapy. Results: Across all participants, the HbA1c values decreased significantly from a baseline of 8.9 (74 mmol/mol) ± 0.14% to 8.2 (66 mmol/mol) ± 0.14% ( P<.01) in the first 3 months, 8.0 (64 mmol/mol) ± 0.12% ( P<.01) at 6 months, to 8.3 (67 mmol/mol) ± 0.14% ( P<.01) at 12 months. There was no significant decrease in weight or TDD with the addition of a GLP-1RA overall or in different insulin groups. However, there was a clinically significant decrease in weight over the study duration. Conclusion: The results of this study suggest that adding a GLP-1RA to various insulin regimens may help to achieve glycemic goals while avoiding the less desirable side effects of weight gain and increasing insulin regimens. However, the expected weight loss and decrease in TDD may not be as sizable in the clinical setting. Abbreviations: DCOE = Diabetes Center of Excellence; DM = diabetes mellitus; GLP-1RA = glucagon-like peptide-1 receptor agonist; HbA1c = hemoglobin A1c; RCT = randomized controlled trial; TDD = total daily dose

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

Metabolism ◽  
2000 ◽  
Vol 49 (6) ◽  
pp. 709-717 ◽  
Author(s):  
Fernando Rodriquez de Fonseca ◽  
Miguel Navarro ◽  
Elvira Alvarez ◽  
Isabel Roncero ◽  
Julie A. Chowen ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Body Weight Loss ◽  
Central Effects ◽  
Receptor Agonists ◽  
Obese Rats ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

A novel GIP analogue, ZP 4165, enhances glucagon‐like peptide‐1‐induced body weight loss and improves glycaemic control in rodents

2017 ◽  
Vol 20 (1) ◽  
pp. 60-68 ◽  
Author(s):  
Pia K. Nørregaard ◽  
Maria A. Deryabina ◽  
Pernille Tofteng Shelton ◽  
Jacob U. Fog ◽  
Jens R. Daugaard ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Glycaemic Control ◽  
Body Weight Loss ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document